Clinical benefit of Neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients

Transplantation

Volumn 68, Issue 12, 1999, Pages 1839-1842

  Cantarovich, Marcelo ^a   Elstein, Eleanor ^a   De Varennes, Benoit ^a   Barkun, Jeffrey S ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN A; PREDNISONE; THYMOCYTE ANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MONITORING; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL;

EID: 0033611084     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199912270-00003     Document Type: Article

References (25)

1. Morris PJ. Cyclosporine A. Transplantation 1981; 32: 349.
2. Miller LW, O'Connell JB. Long-term use of cyclosporine in cardiac transplantation. Transplant Proc 1990; 22: 15.
3. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine associated chronic nephropathy. N Engl J Med 1984; 311: 699.
4. Mihatsch MJ, Thiel G, Spichtin HP, et al. Morphological findings in kidney transplant after treatment with cyclosporine. Transplant Proc 1983; 4: 2821.
5. Platz KP, Mueller AR, Blumhardt G, et al. Nephrotoxicity following orthotopic liver transplantation. Transplantation 1994; 58: 170.
6. Winkler M, Brinkmann C, Jost U, Oldhafer K, Ringe B, Pilchmayr R. Long-term side-effects of cyclosporine-based immunosuppression in patients after liver transplantation. Transplant Proc 1994; 26: 2679.
7. Greenberg A, Egel JW, Thompson ME, et al. Early and late form of cyclosporine nephrotoxicity: studies in cardiac transplant patients. Am J Kidney Dis 1987; 9: 12.
8. Lewis RM, Van Buren CT, Radovancevic B, et al. Impact of long-term cyclosporine immunosuppressive therapy on native kidneys versus renal allografts: serial renal function in heart and kidney transplant recipients. J Heart Lung Transplant 1991; 10: 63.
9. Gonwa TA, Mai ML, Pilcher J, et al. Stability of long-term renal function in heart transplant patients treated with induction therapy and low-dose cyclosporine. J Heart Lung Transplant 1992; 11: 926.
10. Cantarovich M, Fitchett D, Latter D. Cyclosporine trough levels, acute rejection, and renal dysfunction after heart transplantation. Transplantation 1995; 59: 444.
11. Holt DW, Mueller EA, Kovarick JM, van Bree JB, Kutz K. The pharmacokinetics of Sandimmune Neoral: A new oral formulation of cyclosporine. Transplant Proc 1994; 26: 2935.
12. Kahan BD, Dunn J, Fitts C, et al. The Neoral formulation: Improved correlation between Cyclosporine trough levels and exposure in stable renal transplant recipients. Transplant Proc 1994; 26: 2940.
13. Foradori AC, Martinez L, Vacarezza A, Elberg L, Loveluck A, Pinto C. Pharmacokinetics of a new galenical formulation of oral cyclosporine A in stable kidney transplanted patients. Transplant Proc 1994; 26: 2969.
14. Amante AJ, Kahan BD. Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period. Transplant Proc 1996; 28: 2162.
15. Keown P, Landsberg D, Halloran P, et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation 1996; 62: 1744.
16. Gaspari F, Anedda MF, Signorini O, Remuzzi G, Perico N. Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration. J Am Soc Nephrol 1997; 8: 647.
17. Cantarovich M, Besner JG, Barkun JS, Elstein E, Loertscher R. Two hour Cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 1998; 12: 243.
18. Cantarovich M, Barkun JS, Tchervenkov JI, Besner J-G, Metrakos P. Comparison of Neoral dose monitoring with cyclosporine trough levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation 1998; 12: 1621.
19. Zuchelli GC, Pilo A, Chiesa MR, Scarlattini M, Bizollon CA. Progress report of an external quality assessment scheme for cyclosporine assay. Ther Drug Monit 1996; 18: 273.
20. Billingham M, Cary N, Hammond M, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study Group. J Heart Lung Transplant 1990; 9: 587.
21. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 6: 2403.
22. Cole E, Keown P, Landsberg D, et al. Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients: report of the Canadian Neoral Renal Study Group. Transplantation 1998; 65: 505.
23. Uretsky BF, Murali S, Reddy S, et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 1987; 76: 827.
24. Rizeg MN, Masek MA, Billingham ME. Acute rejection: significance of elapsed time after transplantation. J Heart Lung Transplant 1994; 13: 862.
25. Valantine H, Hunt S, Gamberg P, Miller J, Luikart H. Impact of cyclosporine dose on long-term outcome after heart transplantation. Transplant Proc 1994; 26: 2710.